Advanced systemic mastocytosis is a progressive condition characterized by the accumulation of mast cells in the body’s organs. There’s no cure for advanced systemic mastocytosis, but many of the ...

A diagnosis of advanced systemic mastocytosis (advSM), a rare blood disorder in which too many mast cells accumulate in various parts of the body, can cause a range of strong emotions. AdvSM sometimes ...

Advanced systemic mastocytosis is a progressive disorder that causes the atypical buildup of mast cells in different organs in the body. Treatment aims to slow the progression of the condition and ...

Advanced systemic mastocytosis (advSM) is a rare and serious form of systemic mastocytosis, a blood disorder that involves the overproduction of mast cells. Mast cells are a type of white blood cell ...

A drug made by Blueprint Medicines markedly improved symptoms of a rare immune system disorder called non-advanced systemic mastocytosis in a clinical trial that is being closely watched by investors, ...

Systemic mastocytosis is a myeloid neoplasm divided into six subcategories by the recent classification by WHO. It involves the accumulation of abnormal mast cells (MCs) in the skin, liver, spleen, ...

A standard treatment for mastocytosis is difficult to apply to individual patients based on the variable clinical course. A general consensus for using antimediator agents such as antihistamines, ...

Avapritinib (Ayvakit, Blueprint Medicines), a novel agent that targets a specific mutation found in 90% of patients with systemic mastocytosis, reduces skin lesions and mast cell burden, according to ...

—An analysis of registry data concluded that hypersensitivity reactions in patients with mastocytosis are caused by exposure to certain triggers, including low tryptase levels and stings from certain ...

Blueprint Medicines' avapritinib demonstrated significant improvements in patient-reported symptoms and disease burden in indolent systemic mastocytosis (ISM). Avapritinib's safety profile in the ...